- Home
- SLNO vs ARVN Comparison
SLNO vs ARVN Comparison
Compare SLNO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- ARVN
- Stock Information
- Founded
- SLNO 1999
- ARVN 2015
- Country
- SLNO United States
- ARVN United States
- Employees
- SLNO N/A
- ARVN N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- ARVN Health Care
- Exchange
- SLNO Nasdaq
- ARVN Nasdaq
- Market Cap
- SLNO 1.9B
- ARVN 1.7B
- IPO Year
- SLNO 2014
- ARVN 2018
- Fundamental
- Price
- SLNO $54.63
- ARVN $25.11
- Analyst Decision
- SLNO Strong Buy
- ARVN Strong Buy
- Analyst Count
- SLNO 7
- ARVN 13
- Target Price
- SLNO $69.86
- ARVN $61.08
- AVG Volume (30 Days)
- SLNO 504.7K
- ARVN 718.1K
- Earning Date
- SLNO 11-06-2024
- ARVN 10-30-2024
- Dividend Yield
- SLNO N/A
- ARVN N/A
- EPS Growth
- SLNO N/A
- ARVN N/A
- EPS
- SLNO N/A
- ARVN N/A
- Revenue
- SLNO N/A
- ARVN $161,100,000.00
- Revenue This Year
- SLNO N/A
- ARVN $237.44
- Revenue Next Year
- SLNO N/A
- ARVN N/A
- P/E Ratio
- SLNO N/A
- ARVN N/A
- Revenue Growth
- SLNO N/A
- ARVN 1.07
- 52 Week Low
- SLNO $26.38
- ARVN $21.17
- 52 Week High
- SLNO $59.75
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- SLNO 51.30
- ARVN 48.81
- Support Level
- SLNO $50.69
- ARVN $21.17
- Resistance Level
- SLNO $59.75
- ARVN $28.70
- Average True Range (ATR)
- SLNO 2.47
- ARVN 1.72
- MACD
- SLNO -0.48
- ARVN -0.41
- Stochastic Oscillator
- SLNO 43.47
- ARVN 51.44
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.